CNS-active drugs
Posted: Fri Mar 15, 2024 11:27 am
2024 Feb 29
Center for Innovation in Brain Science, University of Arizona, Tucson, AZ, United States
Association between CNS-active drugs and risk of Alzheimer's and age-related neurodegenerative diseases
https://pubmed.ncbi.nlm.nih.gov/38487578/
Conclusion: Collectively, these findings indicate that CNS-active drugs were associated with reduced risk of developing AD and other age-related NDDs. The exception was atypical antipsychotics, which increased risk. Potential use of combination therapy with atypical antipsychotics could mitigate the risk conferred by these drugs. Evidence from these analyses advance precision prevention strategies to reduce the risk of age-related NDDs in persons with neuropsychiatric disorders.
Center for Innovation in Brain Science, University of Arizona, Tucson, AZ, United States
Association between CNS-active drugs and risk of Alzheimer's and age-related neurodegenerative diseases
https://pubmed.ncbi.nlm.nih.gov/38487578/
Conclusion: Collectively, these findings indicate that CNS-active drugs were associated with reduced risk of developing AD and other age-related NDDs. The exception was atypical antipsychotics, which increased risk. Potential use of combination therapy with atypical antipsychotics could mitigate the risk conferred by these drugs. Evidence from these analyses advance precision prevention strategies to reduce the risk of age-related NDDs in persons with neuropsychiatric disorders.